Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Protagonist Therapeutics (PTGX)
NASDAQ:PTGX
RESEARCH TOOLSreports
Holding PTGX?
Track your performance easily
PTGX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$24.22 - $48.89
Previous CloseN/A
Volume120.35K
Average Volume (3M)629.28K
Market Cap
$2.25B
Enterprise Value$2.32B
Total Cash (Recent Filing)$77.60M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)14.1
Beta0.37
Next Earnings
Mar 18, 2025EPS Estimate
0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.67
Shares Outstanding59,598,020
10 Day Avg. Volume544,194
30 Day Avg. Volume629,280
Standard Deviation0.28
R-Squared0.17
Alpha0.04
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)6.94
Price to Cash Flow (P/CF)-20.20
P/FCF Ratio0.00
Enterprise Value/Market Cap1.03
Enterprise Value/Revenue7.17
Enterprise Value/Gross Profit38.70
Enterprise Value/Ebitda13.72
Forecast
1Y Price Target
$58.00Price Target Upside48.26% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
Protagonist Therapeutics News
PremiumCompany Announcements
Protagonist Therapeutics Reports Strong Financial TurnaroundBulls Say, Bears Say
Bulls Say
Clinical Data And SafetyTakeda highlights rusfertide’s convincing clinical data with sustained disease control and a differentiated safety profile.
Efficacy And Symptom ImprovementRusfertide's treatment leads to improvements in symptoms like fatigue, early satiety, and abdominal discomfort in patients with moderate or severe symptoms at baseline.
Partnerships And Market ValidationPTGX’s pipeline has attracted partnerships with Takeda and JNJ, which validates PTGX’s drug discovery and development capabilities.
Bears Say
Conflict Of InterestInvestors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report.
Financial LimitationsHigh valuation and licensing terms are seen as factors that limit financial and M&A upside.
Safety ConcernsTwo additional thrombotic events were reported in high-risk polycythemia vera patients, which might raise concerns regarding safety in this subgroup.
---
Ownership Overview
1.78% Insiders
16.13% Mutual Funds
0.17% Other Institutional Investors
53.25% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
PTGX FAQ
What was Protagonist Therapeutics’s price range in the past 12 months?
Protagonist Therapeutics lowest stock price was $24.22 and its highest was $48.89 in the past 12 months.
What is Protagonist Therapeutics’s market cap?
Protagonist Therapeutics’s market cap is $2.25B.
When is Protagonist Therapeutics’s upcoming earnings report date?
Protagonist Therapeutics’s upcoming earnings report date is Mar 18, 2025 which is in 46 days.
How were Protagonist Therapeutics’s earnings last quarter?
Protagonist Therapeutics released its earnings results on Nov 07, 2024. The company reported -$0.54 earnings per share for the quarter, beating the consensus estimate of -$0.578 by $0.038.
Is Protagonist Therapeutics overvalued?
According to Wall Street analysts Protagonist Therapeutics’s price is currently Undervalued.
Does Protagonist Therapeutics pay dividends?
Protagonist Therapeutics does not currently pay dividends.
What is Protagonist Therapeutics’s EPS estimate?
Protagonist Therapeutics’s EPS estimate is 0.12.
How many shares outstanding does Protagonist Therapeutics have?
Protagonist Therapeutics has 59,598,020 shares outstanding.
What happened to Protagonist Therapeutics’s price movement after its last earnings report?
Protagonist Therapeutics reported an EPS of -$0.54 in its last earnings report, beating expectations of -$0.578. Following the earnings report the stock price went down -2.899%.
Which hedge fund is a major shareholder of Protagonist Therapeutics?
Among the largest hedge funds holding Protagonist Therapeutics’s share is Farallon Capital Management, L.L.C.. It holds Protagonist Therapeutics’s shares valued at 264M.
---
Protagonist Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$58.00 (48.26% Upside)
$58.00 (48.26% Upside)
Blogger Sentiment
Bullish
PTGX Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 1.3M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $11.8M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 0.4%
Last 30 Days ▲ 2.7%
Last 30 Days ▲ 2.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
53.58%
12-Months-Change
Fundamentals
Return on Equity
40.97%
Trailing 12-Months
Asset Growth
82.98%
Trailing 12-Months
Company Description
Protagonist Therapeutics
Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of novel constrained peptide-based drug candidates that address significant unmet medical needs. The firm's initial lead product candidates, PTG-100 and PTG-200, are being developed for moderate-to-severe ulcerative colitis and Crohn's disease, respectively. The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.
---
PTGX Stock 12 Month Forecast
Average Price Target
$58.00
▲(48.26% Upside)
Technical Analysis
Arrowhead Pharmaceuticals
―
Exelixis
―
Ionis Pharmaceuticals
―
Sarepta Therapeutics
―
Enanta Pharmaceuticals
―
Best Analysts Covering PTGX
1 Year
1 Year Success Rate
18/19 ratings generated profit
1 Year Average Return
+71.49%
reiterated a buy rating 2 months ago
Copying Jonathan Wolleben's trades and holding each position for 1 Year would result in 94.74% of your transactions generating a profit, with an average return of +71.49% per trade.
---